Ikeda, Sadakatsu
Schwaederle, Maria
Mohindra, Mandakini
Fontes Jardim, Denis L.
Kurzrock, Razelle
Funding for this research was provided by:
National Cancer Institute (P30 CA016672)
Article History
Received: 1 March 2018
Accepted: 26 April 2018
First Online: 4 June 2018
Ethics approval and consent to participate
: Not applicable
: Dr. Razelle Kurzrock has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant as well as consultant fees from Sequenom, LOXO, and Actuate Therapeutics. Dr. Kurzrock is also a consultant for Genentech. She also has an ownership interest in CureMatch, Inc. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.